比较低剂量与高剂量静脉地塞米松治疗中重度偏头痛患者的随机试验
这项随机双盲研究纳入209例急诊中重度偏头痛成人患者,比较甲氧氯普胺10 mg静脉注射联合地塞米松4 mg与16 mg的疗效。主要结局持续头痛缓解在两组分别为34%与41%,绝对差7%(95%CI -6%至20%)。数据安全监察委员会基于预设标准建议因无效提前终止研究。
要点
- 甲氧氯普胺10 mg联合地塞米松4 mg组持续头痛缓解34/102(34%),16 mg组42/102(41%)。
- 2小时内头痛缓解低剂量组77/104(74%),高剂量组82/105(78%),绝对差4%(95%CI -8%至16%)。
- 急诊离院后一周头痛天数中位数两组均为2天,均值差0.4(95%CI -0.3至1.2)。
核心结论
- 与甲氧氯普胺10 mg静脉注射联用时,地塞米松剂量大于4 mg不太可能使急诊偏头痛患者获益。
- 本研究提供I级证据表明,在同时接受静脉甲氧氯普胺治疗的急诊偏头痛患者中,静脉地塞米松16 mg不太可能比4 mg提供更高的持续头痛缓解率。
研究设计与样本
- 随机双盲研究,纳入符合国际头痛疾病分类第3版偏头痛标准且头痛强度为中重度的成人患者。
- 共筛查1,823例患者,随机分配209例;平均年龄38岁(标准差11),209例中179例(86%)为女性,151例(72%)报告重度头痛,其余为中度。
- 在急诊评估疼痛强度至2小时,并在48小时和7天后通过电话随访。
- 主要结局为持续头痛缓解;次要结局包括2小时内头痛缓解及随后一周头痛天数。
- 数据安全监察委员会依据预设标准建议因无效提前终止研究。
主要发现
- 持续头痛缓解:甲氧氯普胺+4 mg组35/102(34%),甲氧氯普胺+16 mg组42/102(41%),绝对差7%(95%CI -6%至20%)。
- 2小时内头痛缓解:低剂量组77/104(74%),高剂量组82/105(78%),绝对差4%(95%CI -8%至16%)。
- 急诊离院后一周头痛天数:低剂量组中位数2天(第25、75百分位1、5),高剂量组中位数2天(第25、75百分位0、4),均值差0.4(95%CI -0.3至1.2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据安全监察委员会依据预设标准建议因无效提前终止研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Dexamethasone decreases the frequency of migraine recurrence after emergency department (ED) discharge. However, the optimal dose of dexamethasone is unknown. We hypothesized that dexamethasone 16 mg IV would allow greater rates of sustained headache relief than 4 mg when coadministered with metoclopramide 10 mg IV. METHODS: This was a randomized double-blind study. Adults who presented with a headache meeting International Classification of Headache Disorders, 3rd edition, migraine criteria were eligible if they rated the headache as moderate or severe in intensity. Pain intensity was assessed for up to 2 hours in the ED and through telephone 48 hours and 7 days later. The primary outcome was sustained headache relief. Secondary outcomes included headache relief within 2 hours and the number of headache days during the subsequent week. Relying on a priori criteria, the data safety monitoring committee recommended halting the study early for futility. RESULTS: A total of 1,823 patients were screened, and 209 patients were randomized. The mean age was 38 years (SD 11). One hundred seventy-nine of 209 (86%) identified as women. One hundred fifty-one of 209 (72%) of the population reported severe intensity; the rest reported moderate. Thirty-five of 102 (34%) participants in the metoclopramide +4 mg arm achieved sustained headache relief as did 42/102 (41%) participants in the metoclopramide +16 mg arm (absolute difference 7%, 95% CI -6% to 20%). Headache relief within 2 hours occurred in 77/104 (74%) low-dose and 82/105 (78%) high-dose participants (absolute difference 4%, 95% CI -8% to 16%). During the week after ED discharge, low-dose participants reported a median of 2 headache days (25th, 75th percentile 1, 5); in the high-dose arm, this was also 2 (25th, 75th percentile 0, 4) (mean difference 0.4, 95% CI -0.3 to 1.2). DISCUSSION: When added to 10 mg IV metoclopramide, doses of dexamethasone greater than 4 mg are unlikely to benefit patients in the ED with migraine. TRIAL REGISTRATION INFORMATION: This study was registered at ClinicalTrials.gov on October 2, 2019 (NCT04112823). The first patient was enrolled on December 22, 2019. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that 16 mg of IV dexamethasone is unlikely to provide greater rates of sustained headache relief than 4 mg of IV dexamethasone among patients in the ED with migraine treated concurrently with IV metoclopramide.
引用
- Friedman BW, Solorzano C, Kessler BD, et al. Randomized Trial Comparing Low- vs High-Dose IV Dexamethasone for Patients With Moderate to Severe Migraine. Neurology. 2023. PMID: 37604662. doi:10.1212/WNL.0000000000207648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。